NCT00880308 2020-12-19
Dose Finding and Safety of Oral LDE225 in Patients With Advanced Solid Tumors
Novartis
Phase 1 Completed
Clinical Trials
5 trialsNCT01208831 2020-12-19
An East Asian Study of LDE225
Novartis
Phase 1 Completed
NCT01327053 2019-08-28
BOLT
Novartis
Phase 2 Completed
NCT02002689 2016-05-02
SIGNATURE
Novartis
Phase 2 Terminated
NCT01350115 2015-10-19
Efficacy, Safety and Pharmacokinetics of Oral LDE225 in Treatment of Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS)
Novartis
Phase 2 Completed